Gonadotropin-releasing Hormone (GnRH) Antagonist During 3 Days
- Conditions
- Infertility
- Interventions
- Drug: ovarian stimulation
- Registration Number
- NCT01093443
- Lead Sponsor
- Universitair Ziekenhuis Brussel
- Brief Summary
In this prospective study, the investigators would like to show whether ovarian stimulation with pretreatment of a GnRH antagonist during 3 consecutive days at initiation of the cycle, is possible.
- Detailed Description
A recently accepted study demonstrated that raised progesterone levels can be normalized through administration of a GnRH antagonist during three subsequent days prior to the start of gonadotropin stimulation in a GnRH antagonist protocol. This regimen, after normalisation of the progesterone value, allows controlled ovarian hyperstimulation (COH). Since this regimen is valid in case of elevated progesterone, GnRH antagonists pretreatment may prove to be a valid tool for scheduling IVF treatment in patients with normal progesterone values on day 2 of the cycle. In this prospective randomised trial, the investigators study the impact of administration of a GnRH antagonist during 3 consecutive days at initiation of the cycle.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 70
- < 39 years old on day of randomisation
- FSH < 12 (in the early follicular phase)
- Normal ultrasound scan, i.e. presence of both ovaries, without evidence of abnormality within 6 months prior to randomisation.
- Regular menstrual cycles of 21-35 days, presumed to be ovulatory.
- BMI between 18 and 29 (both inclusive)
- 1st or 2nd trial
- IVF or ICSI
- Randomisation at out-patient clinic
- ≥ 39 years old on day of randomisation
- Endometriosis ≥ grade 3
- PCOS
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description A ovarian stimulation Patients undergo a standard treatment with a classical GnRH antagonist protocol. B ovarian stimulation Before undergoing a standard protocol for ovarian stimulation, patients in this group receive a pretreatment with GnRH antagonists during 3 consecutive days
- Primary Outcome Measures
Name Time Method Endocrine profile up to 9 months The purpose is to assess the endocrine profile in each treatment group
- Secondary Outcome Measures
Name Time Method Pregnancy rate up to 9 months The purpose is to study the pregnancy rate in each treatment group
Trial Locations
- Locations (1)
UZ Brussel
🇧🇪Jette, Brussels, Belgium